ArticleFrontiers in nutrition2026
Almond protein and whey protein beverages elicit comparable appetite regulation, gastrointestinal symptoms and hydration responses in postmenopausal women: a randomised crossover trial.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Postmenopausal women experience physiological changes in appetite regulation, gastrointestinal function and hydration that may influence utility of protein supplements. Almond protein powder (APP), a plant-derived by-product of almond oil extraction, provides protein alongside fibre and unsaturated fat, which may influence these outcomes differently from whey protein (WP). Objectives of this study were to compare acute appetite, gastrointestinal and hydration responses to APP, WP, placebo and water ingestion in postmenopausal women. Materials and methods: Nine postmenopausal women (60 ± 4 y) completed a randomised crossover trial involving four treatments: APP (29.5 g protein), WP (29.5 g protein), placebo and water. Appetite and gastrointestinal symptoms (GIS) were assessed over 180 min using visual analogue scales. Hydration outcomes included urine colour, urine specific gravity, urine and plasma osmolality, fluid balance and beverage hydration index (BHI). Outcomes were analysed using linear mixed models with significance accepted at Results: APP and WP suppressed appetite relative to baseline and water during the first 60 min post-ingestion period. Appetite area under the curve differed significantly between water and all other treatments (all Conclusion: APP and WP elicited comparable acute appetite suppression, gastrointestinal tolerance and hydration responses in postmenopausal women. While all nutrient-containing beverages reduced appetite relative to water during the early post-ingestion period, no meaningful differences were observed between APP and WP across appetite, GIS or hydration outcomes. These findings suggest that APP may represent a well-tolerated plant-based alternative to WP for protein supplementation in postmenopausal women. However, given the small sample size and acute nature of the intervention, larger and longer-term studies are required to determine whether these responses translate to habitual use and clinically relevant health outcomes. Clinical trial registration: Identifier 2024/HE000669; ACTRN12625000127404p. https://www.anzctr.org.au.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.